Shares of Suven Life Sciences rose 3.4 percent intraday Thursday as company secured 3 product patents.
The company has been granted 1 product patent from Norway, 1 product patent from South Korea and 1 product patent from Singapore corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027, 2034 and 2036 respectively.
The granted claims of the patents include the class of selective 5-HT6 and 5HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Venkat Jasti, CEO of Suven said, “We are very pleased by the grant of these patents to the company for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
At 10:55 hrs Suven Life Sciences was quoting at Rs 172.50, up Rs 3.30, or 1.95 percent on the BSE.moneycontrol